越来越多的临床研究表明,心肌缺血是一种代谢病。曲美他嗪(万爽力)为哌嗪类衍生物,是一种新型的抗心肌缺血药,是心血管病治疗的辅助药物。主要通过抑制3-酮酰辅酶A硫解酶而抑制心肌脂肪酸B氧化,增加葡萄糖氧化,改善糖酵解与糖氧化耦联,优化心肌细胞能量代谢。尤其是对缺血心肌的作用明显.目前主要用于心绞痛和心功能不全的辅助治疗。大量基础研究证实,万爽力能减少细胞内H+、Na+、Ca2+的超载,抑制氧自由基生成,稳定线粒体膜功能状态,具有抗氧化、抗凋亡等多种细胞保护作用,且不影响血流动力学,无副性肌力作用。本文就万爽力在心血管疾病中的临床 More and more clinical studies have shown that myocardial ischemia is a metabolic disease. Trimetazidine (Wan Shuangli) is a piperazine derivatives, is a new type of anti-ischemic drugs, cardiovascular disease treatment is an auxiliary drug. Inhibition of myocardial fatty acid B oxidation mainly through inhibition of 3-ketoacyl-CoA thiolase increases glucose oxidation, improves glycolysis and carbohydrate oxidative coupling, and optimizes cardiocyte energy metabolism. Especially for the role of ischemic myocardium is obvious now mainly used for angina pectoris and cardiac insufficiency adjuvant therapy. A large number of basic research confirmed that Wanzhuangli can reduce the intracellular H +, Na +, Ca2 + overload, inhibit the generation of oxygen free radicals and stabilize mitochondrial membrane function, with antioxidant, anti-apoptotic and other cytoprotective effects, and does not affect the blood Flow dynamics, no secondary muscle strength. This article Wan Wanli in the clinical cardiovascular disease